Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Consta, Risperdal
2. R 64,766
3. R 64766
4. R-64,766
5. R-64766
6. R64,766
7. R64766
8. Risperdal Consta
9. Risperidal
1. 106266-06-2
2. Risperdal
3. Risperidal
4. Rispolept
5. Risperdal Consta
6. Risperin
7. Rispolin
8. Sequinan
9. Apexidone
10. Risperidonum
11. Risperidona
12. Risperdal M-tab
13. R 64 766
14. Belivon
15. Psychodal
16. Spiron
17. Perseris
18. R 64766
19. R-64766
20. 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
21. Risperidone Impurity K
22. N05ax08
23. Chembl85
24. L6uh7zf8hc
25. 3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-4-one
26. 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
27. Nsc-759895
28. R-64,766
29. R-64-766
30. Risperidal M-tab
31. Chebi:8871
32. Rcn3028
33. Risperidonum [latin]
34. Rcn-3028
35. Risperidona [spanish]
36. 106266-06-2 (free Base)
37. 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-4-one
38. Ncgc00015883-05
39. Ly-03004
40. Cas-106266-06-2
41. Dsstox_cid_25193
42. Dsstox_rid_80740
43. Dsstox_gsid_45193
44. 3-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one
45. 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-
46. Zophrenal
47. R 64,766
48. Risperdal (tn)
49. 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one
50. 3-[2-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
51. 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-4-one
52. 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl}-6,7,8,9-tetrahydro-2-methylpyrido[1,2-a]pyrimidin-4-one
53. 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4h,6h,7h,8h,9h-pyrido[1,2-a]pyrimidin-4-one
54. 4h-pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-
55. Smr000466323
56. Sr-01000075399
57. Unii-l6uh7zf8hc
58. Mfcd00274576
59. Brn 4891881
60. Relday
61. Rispen
62. Okedi
63. Risperidone-ism
64. Hsdb 7580
65. Risperidone???
66. R64766
67. 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-4-one
68. 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
69. Risperidone [usan:usp:inn:ban]
70. Risperidone- Bio-x
71. 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one
72. Ks-1106
73. Risperidone (risperdal)
74. Lopac-r-118
75. Risperidone [mi]
76. Prestwick0_001029
77. Prestwick1_001029
78. Risperidone [inn]
79. Risperidone [jan]
80. R-118
81. Risperidone [hsdb]
82. Risperidone [usan]
83. Gtpl96
84. Risperidone [vandf]
85. Risperidone [mart.]
86. Risperidone(r 64 766)
87. Schembl27911
88. Risperidone [usp-rs]
89. Risperidone [who-dd]
90. Mls000759429
91. Mls001165758
92. Mls001424081
93. Us8802672, Risperidone
94. Bidd:gt0262
95. R 62 766
96. Spbio_003078
97. Risperidone (jp17/usp/inn)
98. Dtxsid8045193
99. Risperidone [ep Impurity]
100. Risperidone [orange Book]
101. Hms1571m19
102. Hms2051h07
103. Hms2089c22
104. Hms2098m19
105. Hms2233o11
106. Hms3373m18
107. Hms3393h07
108. Hms3657g13
109. Hms3715m19
110. Hms3887g15
111. Pharmakon1600-01506038
112. Risperidone [ep Monograph]
113. Risperidone [usp Impurity]
114. Zinc538312
115. Risperidone [usp Monograph]
116. Act04270
117. Bcp08161
118. Risperidone 1.0 Mg/ml In Methanol
119. Tox21_110253
120. Bdbm50001885
121. Cp-018
122. Nsc759895
123. Nsc786035
124. Nsc801188
125. S1615
126. Stk646402
127. Akos005577302
128. Tox21_110253_1
129. Ac-1306
130. Ccg-100930
131. Cs-1619
132. Db00734
133. Ly03004
134. Nc00180
135. Nsc 759895
136. Nsc-786035
137. Nsc-801188
138. Pb26023
139. Risperidone, >=98% (hplc), Powder
140. Ncgc00015883-01
141. Ncgc00015883-02
142. Ncgc00015883-03
143. Ncgc00015883-04
144. Ncgc00015883-06
145. Ncgc00015883-07
146. Ncgc00015883-08
147. Ncgc00015883-11
148. Ncgc00094352-01
149. Ncgc00094352-02
150. Ncgc00094352-03
151. Ncgc00179257-01
152. 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]-pyrimidin-4-one
153. 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
154. 3-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
155. 4h-pyrido(1,2-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2-methyl-
156. Br164349
157. Hy-11018
158. Ab00514010
159. Eu-0101074
160. Ft-0631037
161. Ft-0674432
162. R0087
163. Sw197348-4
164. 66r062
165. D00426
166. Ab00514010-09
167. Ab00514010-11
168. Ab00514010-12
169. Ab00514010_13
170. Ab00514010_14
171. A801409
172. L000510
173. Q412443
174. J-001555
175. Sr-01000075399-2
176. Sr-01000075399-8
177. Brd-k53857191-001-04-5
178. Brd-k53857191-001-10-2
179. Z1522566617
180. Risperidone, British Pharmacopoeia (bp) Reference Standard
181. Risperidone, European Pharmacopoeia (ep) Reference Standard
182. Risperidone, United States Pharmacopeia (usp) Reference Standard
183. Risperidone, Pharmaceutical Secondary Standard; Certified Reference Material
184. Risperidone For System Suitability, European Pharmacopoeia (ep) Reference Standard
185. Risperidone Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
186. (risperidone)3-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one
187. 2-(2-(4-(benzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-7,8,9,9a-tetrahydro-1h-pyrido[1,2-a]pyrimidin-4(6h)-one
188. 2-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-6,7,8,8a-tetrahydro-5h-naphthalen-1-one
189. 3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
190. 3-[2-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
191. 3-[2-[4(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4h-pyrido[1,2-a]pyrimidin-4-one
192. 3-[2-[4-(6 Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
193. 3-[2-[4-(6-fluoro- 1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4h-pyrido[1,2-a]pyrimidin-4-one
194. 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
195. 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
196. 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-me Thyl-4h-pyrido[1,2-a]pyrimidin-4-one
197. 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)-1-piperidyl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one;risperidone
198. 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[2,1-b]pyrimidin-4-one
199. 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl}- 6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
200. 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimid-in-4-one
201. 3-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (resperidone)
202. 3-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one (risperidone)
203. 3-{2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-pyrido[1,2-a]pyrimidin-4-one(risperidone)
204. 3-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydro-4h-pyrido[1,2-a]pyrimidin-4-one
205. 4h-pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benz-isoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-
206. 5-[2-(4-benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-methyl-1,3-dihydro-indol-2-one(norastemizole)
| Molecular Weight | 410.5 g/mol |
|---|---|
| Molecular Formula | C23H27FN4O2 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 410.21180428 g/mol |
| Monoisotopic Mass | 410.21180428 g/mol |
| Topological Polar Surface Area | 61.9 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 731 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Risperdal |
| PubMed Health | Risperidone (Injection) |
| Drug Classes | Antipsychotic |
| Drug Label | RISPERDAL contains risperidone, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[... |
| Active Ingredient | Risperidone |
| Dosage Form | Tablet; Tablet, orally disintegrating; Solution |
| Route | Oral |
| Strength | 1mg/ml; 0.5mg; 1mg; 0.25mg; 4mg; 2mg; 3mg |
| Market Status | Prescription |
| Company | Janssen Pharms |
| 2 of 6 | |
|---|---|
| Drug Name | Risperdal consta |
| PubMed Health | Risperidone (Injection) |
| Drug Classes | Antipsychotic |
| Active Ingredient | Risperidone |
| Dosage Form | Injectable |
| Route | Intramuscular |
| Strength | 25mg/vial; 37.5mg/vial; 12.5mg/vial; 50mg/vial |
| Market Status | Prescription |
| Company | Janssen Pharms |
| 3 of 6 | |
|---|---|
| Drug Name | Risperidone |
| PubMed Health | Risperidone |
| Drug Classes | Antipsychotic |
| Drug Label | RISPERDAL contains risperidone, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[... |
| Active Ingredient | Risperidone |
| Dosage Form | Tablet; Tablet, orally disintegrating; Solution |
| Route | oral; Oral |
| Strength | 1mg/ml; 0.5mg; 1mg; 0.25mg; 4mg; 2mg; 3mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Amneal Pharms; Wockhardt; Ranbaxy; Ani Pharms; West Ward Pharms; Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Taro; Torrent Pharms; Precision Dose; Sandoz; Prosam Labs; Prinston; Cipla; Par Pharm; Roxane; Watson Labs; Jub |
| 4 of 6 | |
|---|---|
| Drug Name | Risperdal |
| PubMed Health | Risperidone (Injection) |
| Drug Classes | Antipsychotic |
| Drug Label | RISPERDAL contains risperidone, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[... |
| Active Ingredient | Risperidone |
| Dosage Form | Tablet; Tablet, orally disintegrating; Solution |
| Route | Oral |
| Strength | 1mg/ml; 0.5mg; 1mg; 0.25mg; 4mg; 2mg; 3mg |
| Market Status | Prescription |
| Company | Janssen Pharms |
| 5 of 6 | |
|---|---|
| Drug Name | Risperdal consta |
| PubMed Health | Risperidone (Injection) |
| Drug Classes | Antipsychotic |
| Active Ingredient | Risperidone |
| Dosage Form | Injectable |
| Route | Intramuscular |
| Strength | 25mg/vial; 37.5mg/vial; 12.5mg/vial; 50mg/vial |
| Market Status | Prescription |
| Company | Janssen Pharms |
| 6 of 6 | |
|---|---|
| Drug Name | Risperidone |
| PubMed Health | Risperidone |
| Drug Classes | Antipsychotic |
| Drug Label | RISPERDAL contains risperidone, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[... |
| Active Ingredient | Risperidone |
| Dosage Form | Tablet; Tablet, orally disintegrating; Solution |
| Route | oral; Oral |
| Strength | 1mg/ml; 0.5mg; 1mg; 0.25mg; 4mg; 2mg; 3mg |
| Market Status | Tentative Approval; Prescription |
| Company | Mylan Pharms; Amneal Pharms; Wockhardt; Ranbaxy; Ani Pharms; West Ward Pharms; Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Sun Pharm Inds; Taro; Torrent Pharms; Precision Dose; Sandoz; Prosam Labs; Prinston; Cipla; Par Pharm; Roxane; Watson Labs; Jub |
Antipsychotic Agents; Dopamine Antagonists; Serotonin Antagonists
National Library of Medicine's Medical Subject Headings. Risperidone. Online file (MeSH, 2014). Available from, as of November 19, 2013: https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html
Risperdal (risperidone) is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Risperdal adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults. /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Risperdal is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years). /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Risperdal is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years). /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
/BOXED WARNING/ WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperdal (risperidone) is not approved for the treatment of patients with dementia-related psychosis.
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Like other antipsychotic agents (e.g., phenothiazines), risperidone has been associated with tardive dyskinesias. Although it has been suggested that atypical antipsychotics appear to have a lower risk of tardive dyskinesia, whether antipsychotic drugs differ in their potential to cause tardive dyskinesia is as yet unknown. In one open-label study, an annual incidence of tardive dyskinesia of 0.3% was reported in patients with schizophrenia who received approximately 8-9 mg of oral risperidone daily for at least 1 year. The prevalence of this syndrome appears to be highest among geriatric patients (particularly females). The risk of developing tardive dyskinesia and the likelihood that it will become irreversible also appear to increase with the duration of therapy and cumulative dose of antipsychotic agents administered; however, the syndrome may occur, although much less frequently, after relatively short periods of treatment with low dosages.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 2514
Neuroleptic malignant syndrome (NMS), a potentially fatal symptom complex, has been reported in patients receiving antipsychotic agents. NMS requires immediate discontinuance of the drug and intensive symptomatic and supportive care.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 2520
Dose-related somnolence was a commonly reported adverse effect associated with risperidone treatment. Approximately 8% of adult patients with schizophrenia receiving 16 mg of oral risperidone daily and 1% of patients receiving placebo reported somnolence in studies utilizing direct questioning or a checklist to detect adverse events, respectively.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 2514
For more Drug Warnings (Complete) data for RISPERIDONE (41 total), please visit the HSDB record page.
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder. Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches. Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.
FDA Label
Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders. Risperidone has a high binding affinity for serotonergic 5-HT2A receptors when compared to dopaminergic D2 receptors in the brain. Risperidone binds to D2 receptors with a lower affinity than first-generation antipsychotic drugs, which bind with very high affinity. A reduction in extrapyramidal symptoms with risperidone, when compared to its predecessors, is likely a result of its moderate affinity for dopaminergic D2 receptors.
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
Serotonin Antagonists
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)
N05AX08
N05AX08
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N05 - Psycholeptics
N05A - Antipsychotics
N05AX - Other antipsychotics
N05AX08 - Risperidone
Absorption
Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.
Route of Elimination
Risperidone is extensively metabolized in the liver. In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives are prolonged compared to young healthy subjects.
Volume of Distribution
The volume of distribution of risperidone is approximately 1 to 2 L/kg.
Clearance
Risperidone is cleared by the kidneys. Clearance is decreased in the elderly and those with a creatinine clearance (ClCr) between 15-59 mL/min, in whom clearance is decreased by approximately 60%.
Risperidone is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Risperidone is rapidly distributed. The volume of distribution is 1-2 L/kg. In plasma, risperidone is bound to albumin and a1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 ug/mL), warfarin (10 ug/mL), and carbamazepine (10 ug/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Plasma concentrations of risperidone, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers. Steady-state concentrations of 9-hydroxyrisperidone are reached in 5-6 days (measured in extensive metabolizers).
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Risperidone and 9-hydroxyrisperidone are present in human breast milk.
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
For more Absorption, Distribution and Excretion (Complete) data for RISPERIDONE (6 total), please visit the HSDB record page.
Extensively metabolized by hepatic cytochrome P450 2D6 isozyme to 9-hydroxyrisperidone (i.e. [paliperidone]), which has approximately the same receptor binding affinity as risperidone. Hydroxylation is dependent on debrisoquine 4-hydroxylase and metabolism is sensitive to genetic polymorphisms in debrisoquine 4-hydroxylase. Risperidone also undergoes N-dealkylation to a lesser extent.
Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone. CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. CYP 2D6 is subject to genetic polymorphism (about 6%-8% of Caucasians, and a very low percentage of Asians, have little or no activity and are "poor metabolizers") and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Risperidone has known human metabolites that include 3-[2-[4-(6-fluoro-2-hydroxy-1,2-benzoxazol-2-ium-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one, 3-ethyl-2,9-dimethyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one, 6-Fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 9-Hydroxy-risperidone, and Paliperidone.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
3 hours in extensive metabolizers Up to 20 hours in poor metabolizers
The apparent half-life of risperidone plus 9-hydroxyrisperidone following Risperdal Consta administration is 3 to 6 days, and is associated with a monoexponential decline in plasma concentrations. This half-life of 3-6 days is related to the erosion of the microspheres and subsequent absorption of risperidone.
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL CONSTA (risperidone) kit (June 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb34ee82-d2c2-43b8-ba21-2825c0954691
The apparent half-life of risperidone was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.
US Natl Inst Health; DailyMed. Current Medication Information for RISPERDAL (risperidone) tablet RISPERDAL M-TAB (risperidone) tablet, orally disintegrating RISPERDAL (risperidone) solution (August 2012). Available from, as of November 11, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7e117c7e-02fc-4343-92a1-230061dfc5e0
Though its precise mechanism of action is not fully understood, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to result from an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. D2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations. Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect. Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors. Low-affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided. Increased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation. The high-affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is therefore not completely inhibited. Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms. Risperidone has also been said to be an antagonist of alpha-1 (1), alpha-2 (2), and histamine (H1) receptors. Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time.
Risperidone has high affinity for several receptors, including serotonin receptors (5-HT 2A/2C), D2 dopamine receptors and alpha1 and H1 receptors. It has no appreciable activity at M1 receptors. Its primary metabolite (9-hydroxyrisperidone) is nearly equipotent compared with the parent compound at D2 and 5-HT 2A receptors.
Goldfrank, L.R., Goldfrank's Toxicologic Emergencies 9th Ed. 2011., McGraw-Hill, New York, N.Y., p. 1006
The exact mechanism of antipsychotic action of risperidone has not been fully elucidated but, like that of clozapine, appears to be more complex than that of most other antipsychotic agents and may involve antagonism of central type 2 serotonergic (5-HT2) receptors and central dopamine D2 receptors.
American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 2517
Risperidone is an atypical antipsychotic drug that is widely prescribed to young patients with different psychotic disorders. The long-term effects of this antipsychotic agent on neuronal receptors in developing brain remain unclear and require further investigation. In this study, we examined the effects of long-term treatment of risperidone on two serotonin receptor subtypes in brain regions of juvenile rat. Levels of 5-HT(1A) and 5-HT(2A) receptors in forebrain regions of juvenile rats were quantified after 3 weeks of treatment with three different doses of risperidone (0.3, 1.0 and 3.0mg/kg). Findings were compared to previously reported changes in 5-HT receptors after risperidone treatment (3.0mg/kg) in adult rat brain. The three doses of risperidone selectively and dose-dependently increased levels of 5-HT(1A) receptors in medial-prefrontal and dorsolateral-frontal cortices of juvenile animals. The higher doses (1.0 and 3.0mg/kg) of risperidone also increased 5-HT(1A) receptor binding in hippocampal CA(1) region of juvenile but not adult rats. In contrast, the three doses of risperidone significantly reduced 5-HT(2A) labeling in medial-prefrontal and dorsolateral-frontal cortices in juvenile as well as in adult animals in an equipotent fashion. 5-HT(1A) and 5-HT(2A) receptors in other forebrain regions were not altered by repeated risperidone treatment. These findings indicate that there are differential effects of risperidone on 5-HT(1A) and 5-HT(2A) receptors in juvenile animals, and that the 5-HT system in developing animals is more sensitive than adults to the long-term effects of risperidone.
PMID:19875272 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819571 Choi YK et al; Eur Neuropsychopharmacol 20 (3): 187-94 (2010)
The main class of atypical antipsychotic drugs (APDs) in current use includes the protypical atypical APD, clozapine, as well as aripiprazole, asenapine, iloperidone, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone. At clinically effective doses, these agents produce extensive blockade of serotonin (5-HT)(2A) receptors, direct or indirect stimulation of 5-HT(1A) receptors, and to a lesser extent, reduction in dopamine (DA) D(2) receptor-mediated neurotransmission. This contrasts with typical APDs, for example haloperidol and perphenazine, which are mainly DA D(2/)D(3) receptor antagonists and have weaker, if any, potency as 5-HT(2A) receptor antagonists. Some, but not all, atypical APDs are also effective 5-HT(2C) receptor inverse agonists or neutral antagonists, 5-HT(6) or 5-HT(7) receptor antagonists. This diverse action on 5-HT receptors may contribute to significant differences in efficacy and tolerability among the atypical APDs. There is considerable preclinical and some clinical evidence that effects on 5-HT receptors contribute to the low risk of producing extrapyramidal side effects, which is the defining characteristic of an atypical APD, the lack of elevation in plasma prolactin levels (with risperidone and 9-hydroxyrisperidone being exceptions), antipsychotic action, and ability to improve some domains of cognition in patients with schizophrenia. The serotonergic actions of the atypical APDs, especially 5-HT(2A) receptor antagonism, are particularly important to the differential effects of typical and atypical APDs to overcome the effects of acute or subchronic administration of N-methyl-d-aspartate (NMDA) receptor antagonists, such as phencyclidine, ketamine, and dizocipline (MK-801). 5-HT(1A) receptor stimulation and 5-HT(6) and 5-HT(7) receptor antagonism may contribute to beneficial effects of these agents on cognition. In particular, 5-HT(7) receptor antagonism may be the basis for the pro-cognitive effects of the atypical APD, amisulpride, a D(2)/D(3) receptor antagonist, which has no effect on other 5-HT receptor. 5-HT(2C) receptor antagonism appears to contribute to the weight gain produced by some atypical APDs and may also affect cognition and psychosis via its influence on cortical and limbic dopaminergic activity.
PMID:21420906 Meltzer HY, Massey BW; Curr Opin Pharmacol 11 (1): 59-67 (2011)
Paliperidone is an active metabolite of the second-generation atypical antipsychotic, risperidone recently approved for the treatment of schizophrenia and schizoaffective disorder. Because paliperidone differs from risperidone by only a single hydroxyl group, questions have been raised as to whether there are significant differences in the effects elicited between these two drugs. /The researchers/ compared the relative efficacies of paliperidone versus risperidone to regulate several cellular signalling pathways coupled to four selected GPCR targets that are important for either therapeutic or adverse effects: human dopamine D2 , human serotonin 2A receptor subtype (5-HT2A ), human serotonin 2C receptor subtype and human histamine H1 receptors. Whereas the relative efficacies of paliperidone and risperidone were the same for some responses, significant differences were found for several receptor-signalling systems, with paliperidone having greater or less relative efficacy than risperidone depending upon the receptor-response pair. Interestingly, for 5-HT2A -mediated recruitment of beta-arrestin, 5-HT2A -mediated sensitization of ERK, and dopamine D2 -mediated sensitization of adenylyl cyclase signalling, both paliperidone and risperidone behaved as agonists. These results suggest that the single hydroxyl group of paliperidone promotes receptor conformations that can differ from those of risperidone leading to differences in the spectrum of regulation of cellular signal transduction cascades. Such differences in signalling at the cellular level could lead to differences between paliperidone and risperidone in therapeutic efficacy or in the generation of adverse effects.
PMID:23826915 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791992 Clarke WP et al; Br J Pharmacol 170 (3): 532-45 (2013)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
GDUFA
DMF Review : Complete
Rev. Date : 2021-03-02
Pay. Date : 2020-09-29
DMF Number : 18257
Submission : 2005-04-11
Status : Active
Type : II
Inke S.A: APIs manufacturing plant.
GDUFA
DMF Review : Complete
Rev. Date : 2021-06-09
Pay. Date : 2021-06-04
DMF Number : 15682
Submission : 2001-10-23
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2021-02-23
Pay. Date : 2021-02-18
DMF Number : 16902
Submission : 2003-10-10
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2017-07-21
Pay. Date : 2017-06-22
DMF Number : 15604
Submission : 2001-08-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17260
Submission : 2004-03-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16978
Submission : 2003-11-19
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-09-19
Pay. Date : 2022-09-14
DMF Number : 16963
Submission : 2003-11-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11438
Submission : 1995-04-11
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-11-05
Pay. Date : 2019-10-18
DMF Number : 16517
Submission : 2003-04-08
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Inke S.A: APIs manufacturing plant.
About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Temad- We think of world-class quality.
About the Company : Established in 1997, Temad Co. is one of the largest producers of APIs in Iran & an innovative manufacturer of narcotic and non-narcotic products of world-class quality in the Midd...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Jai Radhe Sales is your partner for all your sourcing needs.
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
About the Company : Zeon Pharma Industries India Pvt ltd is an ISO & GMP certified manufacturer of Bulk drugs & Intermediate and also supplies our associate manufacturing plant API / Semi finish form...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
JPN Pharma offers excellence in API manufacturing through precision, innovation & quality, delivering solutions to the pharma industry
About the Company : JPN Pharma is a premier pharmaceutical company in India, specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and drug intermediates. Headq...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Uzedy (risperidone) is an extended-release 5HT2a/D2 receptor Inhibitor injectable suspension, being investigated for the maintenance treatment of BP-I in adults.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: Uzedy
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: MedinCell
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2025
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : MedinCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva, Medincell Get FDA Acceptance for UZEDY in Bipolar I Disorder
Details : Uzedy (risperidone) is an extended-release 5HT2a/D2 receptor Inhibitor injectable suspension, being investigated for the maintenance treatment of BP-I in adults.
Product Name : Uzedy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2025
Details:
The collaboration aims to advance the Lynra late-stage product LYN-005 (risperidone), which is being evaluated for the treatment of Schizophrenia.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYN-005
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Lyndra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 15, 2025
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Lyndra Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lyndra, Thermo Fisher Partner on Long-Acting Oral Therapy Development
Details : The collaboration aims to advance the Lynra late-stage product LYN-005 (risperidone), which is being evaluated for the treatment of Schizophrenia.
Product Name : LYN-005
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 15, 2025
Details:
LYN-005 (oral weekly risperidone), is being evaluated in phase 3 clinical trials for the treatment of people living with schizophrenia and bipolar 1 disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYN-005
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2024
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lyndra Therapeutics Announces Positive Data from Phase 3 Study of Weekly Oral Risperidone
Details : LYN-005 (oral weekly risperidone), is being evaluated in phase 3 clinical trials for the treatment of people living with schizophrenia and bipolar 1 disorder.
Product Name : LYN-005
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2024
Details:
The financing will obtain access to technology for certain compounds while developing novel pharmaceutical delivery systems, including LYN-005 (risperidone) for schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYN-005
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 01, 2024
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $30.0 million
Deal Type : Financing
Sun Pharma to Acquire 16.7% Stake in Lyndra Therapeutics for $30 mn
Details : The financing will obtain access to technology for certain compounds while developing novel pharmaceutical delivery systems, including LYN-005 (risperidone) for schizophrenia and bipolar I disorder.
Product Name : LYN-005
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 01, 2024
Details:
The net proceeds will support the development of Lyndra’s pipeline, including oral weekly LYN-005 (risperidone), which is near completion of a pivotal phase 3 study and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYN-005
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Sarissa Capital
Deal Size: $101.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing December 25, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Sarissa Capital
Deal Size : $101.0 million
Deal Type : Series E Financing
Lyndra Therapeutics Raises US$101 Million in Series E Funding
Details : The net proceeds will support the development of Lyndra’s pipeline, including oral weekly LYN-005 (risperidone), which is near completion of a pivotal phase 3 study and is being developed for the treatment of people living with schizophrenia and bipola...
Product Name : LYN-005
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 25, 2023
Details:
DLP-114 is an investigational therapy that employs Delpor's proprietary technology platform. It is placed sub-dermally to provide continuous and consistent dosing of risperidone for schizophrenia maintenance therapy lasting 6-12 months.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: DLP-114
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 16, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DLP-114 is an investigational therapy that employs Delpor's proprietary technology platform. It is placed sub-dermally to provide continuous and consistent dosing of risperidone for schizophrenia maintenance therapy lasting 6-12 months.
Product Name : DLP-114
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2023
Details:
Oral weekly LYN-005 (risperidone) is a serotonin and norepinephrine reuptake inhibitor and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: LYN-005
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 05, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oral weekly LYN-005 (risperidone) is a serotonin and norepinephrine reuptake inhibitor and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.
Product Name : LYN-005
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2023
Details:
Uzedy (risperidone) is a dopamine type 2 (D2) and serotonin type 2 (5HT2) receptor antagonist. It is indicated for the treatment of schizophrenia in adults.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: mdc-IRM
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: MedinCell
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 28, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : MedinCell
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Sus...
Details : Uzedy (risperidone) is a dopamine type 2 (D2) and serotonin type 2 (5HT2) receptor antagonist. It is indicated for the treatment of schizophrenia in adults.
Product Name : mdc-IRM
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2023
Details:
Rykindo® (risperidone) is an atypical antipsychotic for the treatment of schizophrenia anfd as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. It acts as combined D2 and 5HT2 receptor antagonist.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: Rykindo
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 15, 2023
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Luye Pharma’s Rykindo® for the Treatment of Schizophrenia and Bipolar 1 Disorder
Details : Rykindo® (risperidone) is an atypical antipsychotic for the treatment of schizophrenia anfd as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. It acts as combined D2 and 5HT2 re...
Product Name : Rykindo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2023
Details:
TV-46000 is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology in combination with a well-characterized molecule, risperidone, that is in clinical development as a treatment for schizophrenia.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Brand Name: mdc-IRM
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: European Investment Bank
Deal Size: $41.8 million Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2022
Lead Product(s) : Risperidone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : European Investment Bank
Deal Size : $41.8 million
Deal Type : Agreement
France : EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innov...
Details : TV-46000 is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology in combination with a well-characterized molecule, risperidone, that is in clinical development as a treatment for schizophrenia.
Product Name : mdc-IRM
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 2MG
Approval Date : 2011-08-24
Application Number : 201003
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : RISPERIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 1MG
Approval Date : 2008-09-15
Application Number : 77953
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 3MG
Approval Date : 2024-06-26
Application Number : 205104
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 4MG
Approval Date : 2011-11-29
Application Number : 77493
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 0.25MG
Approval Date : 2008-10-08
Application Number : 78269
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 1MG
Approval Date : 2009-10-16
Application Number : 78528
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET, ORALLY DISINTEGRATING;ORAL
Dosage Strength : 3MG
Approval Date : 2009-11-30
Application Number : 77328
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET, ORALLY DISINTEGRATING;ORAL
Dosage Strength : 0.5MG
Approval Date : 2010-08-06
Application Number : 77542
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : RISPERIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 3MG
Approval Date : 2014-03-10
Application Number : 78036
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : RISPERIDONE
Dosage Form : TABLET, ORALLY DISINTEGRATING;ORAL
Dosage Strength : 3MG
Approval Date : 2013-04-08
Application Number : 78464
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 0.25MG
USFDA APPLICATION NUMBER - 20272
DOSAGE - TABLET;ORAL - 0.5MG
USFDA APPLICATION NUMBER - 20272
DOSAGE - TABLET;ORAL - 1MG
USFDA APPLICATION NUMBER - 20272
DOSAGE - TABLET;ORAL - 2MG
USFDA APPLICATION NUMBER - 20272
DOSAGE - TABLET;ORAL - 3MG
USFDA APPLICATION NUMBER - 20272
DOSAGE - TABLET;ORAL - 4MG
USFDA APPLICATION NUMBER - 20272
Related Excipient Companies
Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Capital Farma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Doshion Polyscience
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Symrise
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Disintegrants & Superdisintegrants
Direct Compression
Taste Masking
Thickeners and Stabilizers
Granulation
Lubricants & Glidants
Controlled & Modified Release
Chewable & Orodispersible Aids
Solubilizers
Topical
Film Formers & Plasticizers
Parenteral
Co-Processed Excipients
Rheology Modifiers
Empty Capsules
API Stability Enhancers
Emulsifying Agents
Coloring Agents
Vegetarian Capsules
Surfactant & Foaming Agents
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory FDF Prices
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 642
2019 Revenue in Millions : 688
Growth (%) : -7
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 592
2020 Revenue in Millions : 642
Growth (%) : -8
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 485
2021 Revenue in Millions : 592
Growth (%) : -18
Main Therapeutic Indication : Psychiatry/Psychology
Currency : USD
2024 Revenue in Millions : 117
2023 Revenue in Millions : 23
Growth (%) : 409
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -9.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 1,190
2014 Revenue in Millions : 970
Growth (%) : -18%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 893
2015 Revenue in Millions : 970
Growth (%) : -8
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 805
2016 Revenue in Millions : 893
Growth (%) : -10
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 737
2017 Revenue in Millions : 805
Growth (%) : -8%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 688
2018 Revenue in Millions : 737
Growth (%) : -7
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2031-05-31
US Patent Number : 11752092
Drug Substance Claim :
Drug Product Claim :
Application Number : 214835
Patent Use Code : U-3941
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-31
Patent Expiration Date : 2031-05-31
US Patent Number : 11752094
Drug Substance Claim :
Drug Product Claim :
Application Number : 214835
Patent Use Code : U-3942
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-31
Patent Expiration Date : 2031-05-31
US Patent Number : 10195138
Drug Substance Claim :
Drug Product Claim :
Application Number : 214835
Patent Use Code : U-3943
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-05-31
Patent Expiration Date : 2040-09-11
US Patent Number : 12128132
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213586
Patent Use Code : U-543
Delist Requested :
Patent Use Description : TREATMENT OF SCHIZOPHR...
Patent Expiration Date : 2040-09-11
Patent Expiration Date : 2027-11-12
US Patent Number : 8741327
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213586
Patent Use Code : U-543
Delist Requested :
Patent Use Description : TREATMENT OF SCHIZOPHR...
Patent Expiration Date : 2027-11-12
Patent Expiration Date : 2025-01-12
US Patent Number : 9439905
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213586
Patent Use Code : U-543
Delist Requested :
Patent Use Description : TREATMENT OF SCHIZOPHR...
Patent Expiration Date : 2025-01-12
Patent Expiration Date : 2032-04-10
US Patent Number : 11110094
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212849
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-04-10
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2032-04-10
US Patent Number : 9532991
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212849
Patent Use Code : U-3513
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-04-10
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
BioAnalytical Methods
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Analytical Methods
ABOUT THIS PAGE
63
PharmaCompass offers a list of Risperidone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Risperidone manufacturer or Risperidone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Risperidone manufacturer or Risperidone supplier.
PharmaCompass also assists you with knowing the Risperidone API Price utilized in the formulation of products. Risperidone API Price is not always fixed or binding as the Risperidone Price is obtained through a variety of data sources. The Risperidone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Risperdal Consta manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Risperdal Consta, including repackagers and relabelers. The FDA regulates Risperdal Consta manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Risperdal Consta API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Risperdal Consta manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Risperdal Consta supplier is an individual or a company that provides Risperdal Consta active pharmaceutical ingredient (API) or Risperdal Consta finished formulations upon request. The Risperdal Consta suppliers may include Risperdal Consta API manufacturers, exporters, distributors and traders.
click here to find a list of Risperdal Consta suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Risperdal Consta DMF (Drug Master File) is a document detailing the whole manufacturing process of Risperdal Consta active pharmaceutical ingredient (API) in detail. Different forms of Risperdal Consta DMFs exist exist since differing nations have different regulations, such as Risperdal Consta USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Risperdal Consta DMF submitted to regulatory agencies in the US is known as a USDMF. Risperdal Consta USDMF includes data on Risperdal Consta's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Risperdal Consta USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Risperdal Consta suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Risperdal Consta Drug Master File in Japan (Risperdal Consta JDMF) empowers Risperdal Consta API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Risperdal Consta JDMF during the approval evaluation for pharmaceutical products. At the time of Risperdal Consta JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Risperdal Consta suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Risperdal Consta Drug Master File in Korea (Risperdal Consta KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Risperdal Consta. The MFDS reviews the Risperdal Consta KDMF as part of the drug registration process and uses the information provided in the Risperdal Consta KDMF to evaluate the safety and efficacy of the drug.
After submitting a Risperdal Consta KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Risperdal Consta API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Risperdal Consta suppliers with KDMF on PharmaCompass.
A Risperdal Consta CEP of the European Pharmacopoeia monograph is often referred to as a Risperdal Consta Certificate of Suitability (COS). The purpose of a Risperdal Consta CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Risperdal Consta EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Risperdal Consta to their clients by showing that a Risperdal Consta CEP has been issued for it. The manufacturer submits a Risperdal Consta CEP (COS) as part of the market authorization procedure, and it takes on the role of a Risperdal Consta CEP holder for the record. Additionally, the data presented in the Risperdal Consta CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Risperdal Consta DMF.
A Risperdal Consta CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Risperdal Consta CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Risperdal Consta suppliers with CEP (COS) on PharmaCompass.
A Risperdal Consta written confirmation (Risperdal Consta WC) is an official document issued by a regulatory agency to a Risperdal Consta manufacturer, verifying that the manufacturing facility of a Risperdal Consta active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Risperdal Consta APIs or Risperdal Consta finished pharmaceutical products to another nation, regulatory agencies frequently require a Risperdal Consta WC (written confirmation) as part of the regulatory process.
click here to find a list of Risperdal Consta suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Risperdal Consta as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Risperdal Consta API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Risperdal Consta as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Risperdal Consta and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Risperdal Consta NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Risperdal Consta suppliers with NDC on PharmaCompass.
Risperdal Consta Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Risperdal Consta GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Risperdal Consta GMP manufacturer or Risperdal Consta GMP API supplier for your needs.
A Risperdal Consta CoA (Certificate of Analysis) is a formal document that attests to Risperdal Consta's compliance with Risperdal Consta specifications and serves as a tool for batch-level quality control.
Risperdal Consta CoA mostly includes findings from lab analyses of a specific batch. For each Risperdal Consta CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Risperdal Consta may be tested according to a variety of international standards, such as European Pharmacopoeia (Risperdal Consta EP), Risperdal Consta JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Risperdal Consta USP).
